Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Yefei Rong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3096-7883; OpenAlex author ID A5049998807. Sources: OpenAlex.

Their work

Papers
31 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

2012: 3 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 4 papers · 2020: 5 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper

Papers 31

  1. The DIAPH3/RPL6 axis regulates the cGAS-STING pathway in pancreatic cancer. Last author DOI 10.1186/s40001-025-03525-z↗
  2. Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.13643↗
  3. Identification of Novel Tumor Pyroptosis-Related Antigens and Pyroptosis Subtypes for Developing mRNA Vaccines in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/biomedicines12040726↗
  4. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  5. NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1. Co-author DOI 10.1007/s10620-022-07671-w↗
  6. Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer. First author DOI 10.1080/15384101.2021.2014254↗
  7. [Pancreas multidisciplinary team optimizes the diagnosis and treatment of pancreas-related diseases and improves the prognosis of pancreatic cancer patients]. Co-author DOI 10.3760/cma.j.cn112139-20220408-00149↗
  8. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.61498↗
  9. Upregulated circRNA hsa_circ_0071036 promotes tumourigenesis of pancreatic cancer by sponging miR-489 and predicts unfavorable characteristics and prognosis. Co-author DOI 10.1080/15384101.2021.1874684↗
  10. DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. Co-author DOI 10.1111/jcmm.16196↗
  11. PRMT1 promotes pancreatic cancer growth and predicts poor prognosis. Co-author DOI 10.1007/s13402-019-00435-1↗
  12. Author Correction: PRMT1 promotes pancreatic cancer growth and predicts poor prognosis. Co-author DOI 10.1007/s13402-019-00480-w↗
  13. piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Co-author DOI 10.1038/s41556-020-0486-z↗
  14. Author Correction: piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Co-author DOI 10.1038/s41556-020-0520-1↗
  15. Correction: KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis Co-author DOI 10.1158/0008-5472.can-20-2503↗
  16. TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. Last author DOI 10.1007/s10238-018-00543-6↗
  17. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Co-author DOI 10.1016/j.canlet.2019.06.013↗
  18. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2019.111543↗
  19. Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis. Co-author DOI 10.2147/ott.s176101↗
  20. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Co-author DOI 10.1080/15384101.2017.1405194↗
  21. KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-16-1898↗
  22. SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells. Co-author DOI 10.1177/1010428317695913↗
  23. Overexpression of miR-135b-5p promotes unfavorable clinical characteristics and poor prognosis via the repression of SFRP4 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.19150↗
  24. Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pa… Co-author DOI 10.1007/s00262-015-1775-4↗
  25. High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1038/srep39044↗
  26. Long-term survival following total pancreatectomy and superior mesenteric-portal vein resection for pancreatic ductal adenocarcinoma: A case report. Co-author DOI 10.3892/ol.2014.2628↗
  27. TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells. Co-author DOI 10.1007/s12032-014-0260-9↗
  28. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Co-author DOI 10.1007/s13277-013-0679-1↗
  29. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10238-011-0159-0↗
  30. IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Co-author DOI 10.1007/s13277-011-0273-3↗
  31. Primary small cell carcinoma of the pancreas: rare type of pancreatic cancer and review of the literatures. First author DOI 10.1186/1477-7819-10-32↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tiantao Kuang · 17 shared papers, 2012–2024 · strength 1.74
  2. Dansong Wang · 15 shared papers, 2012–2024 · strength 1.36
  3. Wenhui Lou · 12 shared papers, 2012–2024 · strength 1.18
  4. Wenhui Lou · 10 shared papers, 2013–2023 · strength 1.07
  5. Wenchuan Wu · 11 shared papers, 2012–2024 · strength 0.97
  6. Xuefeng Xu · 8 shared papers, 2015–2024 · strength 0.92
  7. Jianang Li · 6 shared papers, 2019–2023 · strength 0.82
  8. Dayong Jin · 11 shared papers, 2012–2024 · strength 0.79
  9. Weilin Mao · 4 shared papers, 2019–2023 · strength 0.63
  10. Yuan Fang · 5 shared papers, 2019–2021 · strength 0.52
  11. Xu Han · 4 shared papers, 2017–2021 · strength 0.41
  12. Wenhui Lou · 5 shared papers, 2012–2024 · strength 0.38
  13. Xi Guo · 2 shared papers, 2024 · strength 0.38
  14. Yingbin Liu · 4 shared papers, 2017–2020 · strength 0.35
  15. Peng Yuan · 4 shared papers, 2017–2020 · strength 0.35
  16. Mo‐Fang Liu · 4 shared papers, 2017–2020 · strength 0.35
  17. Haoyang Huang · 1 shared paper, 2025 · strength 0.33
  18. Yuhong Zhou · 2 shared papers, 2024 · strength 0.33
  19. Wentao Zhou · 3 shared papers, 2017–2021 · strength 0.30
  20. Yaolin Xu · 2 shared papers, 2021–2024 · strength 0.29
  21. Jian-ang Li · 3 shared papers, 2018–2021 · strength 0.27
  22. Lei Zhang · 2 shared papers, 2015–2022 · strength 0.24
  23. Qiaowei Lin · 1 shared paper, 2024 · strength 0.23
  24. Yuhong Zhou · 1 shared paper, 2024 · strength 0.23
  25. Mengmeng Liu · 2 shared papers, 2020 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.